Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Meeting Report
  • Published:

An update on graft-versus-host and graft-versus-leukemia reactions: a summary of the sixth International Symposium held in Schloss Ellmau, Germany, January 22–24, 2004

Bone Marrow Transplantation volume 34, pages 767–780 (2004)Cite this article

Summary:

The Sixth International Symposium on Graft-versus-Host and Graft-versus Leukemia Reactions was held in Schloss Ellmau (near Garmisch-Partenkirchen, Germany) between January 21 and 24, 2004. A total of 110 invited participants (scientists and clinicians working in the area of allogeneic stem cell transplantation) discussed current topics. Major topics of the 2004 meeting were: clinical results of donor lymphocyte infusions, basic biology, immunogenetics, function and clinical relevance of natural killer cells, haplo-identical stem cell transplantation, immune monitoring and immune modulation. Further highlights were: adoptive immunotherapy, vaccination and antibody-mediated strategies. As can be seen in the summaries of the individual presentations, important advances have occurred in our understanding of GVH and GVL reactions. Each session was followed by an animated discussion, which resulted in new ideas, insights and projects both for basic research and clinical transplantation. This year's symposium (‘From Marrow Transplantation to Cell Therapy’) was jointly organized by the Ludwigs-Maximilians-University of Munich (Sonderforschungsbereich 455), GSF (National Research Center for Environment and Health) and the EBMT Immunobiology Working Party. The organizers and authors of the conference proceedings would like to extend their gratitude to all participants for sharing their ideas, slides and manuscripts and making this event possible.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

References

  1. Guglielmi C, Arcese W, Dazzi F et al. Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood 2002; 100: 397–405.

    Article  CAS  Google Scholar 

  2. Schmid C, Alessandrino E, Bunjes D et al. Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with donor lymphocyte transfusion – a retrospective analysis of EBMT results (abstract). Blood 2000; 96: 477a.

    Google Scholar 

  3. Woiciechowsky A, Regn S, Kolb HJ et al. Leukemic dendritic cells generated in the presence of FLT3 ligand have the capacity to stimulate an autologous leukemia-specific cytotoxic T cell response from patients with acute myeloid leukemia. Leukemia 2001; 15: 246–255.

    Article  CAS  Google Scholar 

  4. Schmid C, Schleuning M, Aschan J et al. Low dose Ara C, donor cells and GM-CSF for treatment of recurrent acute myeloid leukemia after allogeneic stem cell transplantation. Leukemia 2004; 18: 1430–1433.

    Article  CAS  Google Scholar 

  5. Kolb HJ, Schmid C, Barrett AJ et al. Graft-versus-leukemia reactions in allogeneic chimeras. Blood 2004; 103: 767–776.

    Article  CAS  Google Scholar 

  6. Nijmeijer BA, Mollevanger P, van Zelderen-Bhola SL et al. Monitoring of engraftment and progression of acute lymphoblastic leukemia in individual NOD/SCID mice. Exp Hematol 2001; 29: 322–329.

    Article  CAS  Google Scholar 

  7. Nijmeijer BA, Willemze R, Falkenburg JHF . JHF An animal model for human cellular immunotherapy: specific eradication of human acute lymphoblastic leukemia by cytotoxic T lymphocytes in NOD/scid mice. Blood 2002; 100: 654–660.

    Article  CAS  Google Scholar 

  8. Peggs K, Thomson K, Hart DP et al. Dose escalated donor lymphocyte infusions following reduced intensity transplantation. Blood 2004; 103: 1548–1556.

    Article  CAS  Google Scholar 

  9. Salama M, Neville T, Marcellus D et al. Donor leukocyte infusion for multiple myeloma. Bone Marrow Transplant 2000; 26: 1179–1184.

    Article  CAS  Google Scholar 

  10. Lockhurst HM, Schattenberg A, Cornellissen JJ et al. Donor lymphocyte infusion for relapsed multiple myeloma after allogeneic stem cell transplantation: predictive factors for response and long term outcome. J Clin Oncol 2000; 18: 3031–3037.

    Article  Google Scholar 

  11. Bellucci R, Wu CJ, Chiaretti S et al. Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens. Blood 2004; 103: 656–663.

    Article  CAS  Google Scholar 

  12. Luft T, Moos M, Goldschmidt H et al. Dissociation of putative graft-versus-haematopoiesis and graft-versus-myeloma effects in patients with rapidly progressive multiple myeloma. Br J Haematol 2003; 123: 646–653.

    Article  Google Scholar 

  13. Ruggeri L, Capanni M, Urbani E et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097–2100.

    Article  CAS  Google Scholar 

  14. Giebel S, Locatelli F, Lamparelli T et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 2003; 102: 814–819.

    Article  CAS  Google Scholar 

  15. Moretta L, Moretta A . Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J 2004; 23: 255–259.

    Article  CAS  Google Scholar 

  16. Bottino C, Castriconi R, Pende D et al. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med 2003; 198: 557–567.

    Article  CAS  Google Scholar 

  17. Ferlazzo G, Tsang ML, Moretta L et al. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med 2002; 195: 343–351.

    Article  CAS  Google Scholar 

  18. Moretta A . Natural killer cells and dendritic cells: rendezvous in abused tissues. Nat Rev Immunol 2002; 12: 957–964.

    Article  Google Scholar 

  19. Moretta A, Bottino C, Vitale M et al. Activating receptors and coreceptors involved in the natural cytolysis. Annu Rev Immunol 2001; 19: 197–223.

    Article  CAS  Google Scholar 

  20. Wagner H . The immunobiology of the toll like receptor 9 (TLR9) subfamily (review). Trends in Immunology (2004); 25: 381–386.

    Article  CAS  Google Scholar 

  21. Reisner Y, Gur H, Reich-Zeliger S et al. Hematopoietic stem cell transplantation across major genetic barriers: tolerance induction by megadose CD34 cells and other veto cells. Ann NY Acad Sci 2003; 996: 72–79.

    Article  CAS  Google Scholar 

  22. Bachar-Lustig E, Reich-Zeliger S, Reisner Y . Anti-third party veto CTLs overcome rejection of hematopoietic allografts: synergism with rapamycin and BM cell dose. Blood 2003; 102: 1943–1950.

    Article  CAS  Google Scholar 

  23. Talvensaari K, Clave E, Douay C et al. A broad T-cell repertoire and an efficient thymic function indicate a favorable long-term immune reconstitution after cord blood stem cell transplantation. Blood 2002; 99: 1458–1464.

    Article  CAS  Google Scholar 

  24. Clave E, Agbalika F, Bajzik V et al. Epstein–Barr virus (EBV) reactivation in allogeneic stem-cell transplantation: relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy. Transplantation 2004; 77: 76–84.

    Article  CAS  Google Scholar 

  25. Reddy P, Maeda Y, Hotary H et al. Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc Natl Acad Sci USA 2004; 101: 3921–3926.

    Article  CAS  Google Scholar 

  26. Keilholz U, Weber J, Finke JH et al. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother 2002; 25: 97–138.

    Article  Google Scholar 

  27. Mailänder V, Scheibenbogen C, Thiel E et al. Complete remission in patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity. Leukemia 2004; 18: 165–166.

    Article  Google Scholar 

  28. Moosmann A, Khan N, Cobbold M et al. B cells immortalized by a mini-Epstein–Barr virus encoding a foreign antigen efficiently reactivate specific cytotoxic T cells. Blood 2002; 100: 1755–1764.

    CAS  PubMed  Google Scholar 

  29. Weissinger EM, Wittke S, Kaiser T et al. Proteomic patterns established with capillary electrophoresis and mass spectrometry for diagnostic purposes. Kidney Int 2004; 65: 2426–2434.

    Article  CAS  Google Scholar 

  30. Kaiser T, Wittke S, Krebs R et al. Capillary electrophoresis coupled to mass spectrometer for automated and robust polypeptide recognition in body fluids for clinical use. Electrophoresis 2004; 25: 2044–2055.

    Article  CAS  Google Scholar 

  31. Dickinson A et al. Non-HLA Immunogenetics and Role in Transplant Outcome. EBMT Handbook: Barcelona, 2004, pp 57–64 (Chapter 3).

    Google Scholar 

  32. Lin MT, Storer B, Martin PJ et al. Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N Engl J Med 2003; 349: 2201–2210.

    Article  CAS  Google Scholar 

  33. Rocha V, Franco RF, Porcher R et al. Host defense and inflammatory gene polymorphisms are associated with outcomes after HLA-identical sibling bone marrow transplantation. Blood 2002; 100: 3908–3918.

    Article  CAS  Google Scholar 

  34. Rezvani K, Grube M, Brenchley JM et al. Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood 2003; 102: 2892–2900.

    Article  CAS  Google Scholar 

  35. Canque B, Camus S, Dalloul A et al. Characterization of dendritic cell differentiation pathways from cord blood CD34(+)CD7(+)CD45RA(+) hematopoietic progenitor cells. Blood 2000; 96: 3748–3756.

    CAS  PubMed  Google Scholar 

  36. Hartwig UF, Robbers M, Wickenhauser C et al. Murine acute graft-versus-host disease can be prevented by depletion of alloreactive T lymphocytes using activation-induced cell death. Blood 2002; 99: 3041–3049.

    Article  CAS  Google Scholar 

  37. Veelken H, Mauerer K, Mikesch K et al. Immune responses and clinical outcome of patients with advanced non-Hodgkin's lymphoma after immunization with a novel recombinant idiotype vaccine. Blood 2003; 102: 898a (abstract 3342).

    Google Scholar 

  38. Jung G, Grosse-Hovest L, Krammer PH et al. Target cell restricted triggering of the CD95 (APO-1/Fas) death receptor with bispecific antibody fragments. Cancer Res 2001; 61: 1846–1848.

    CAS  PubMed  Google Scholar 

  39. Wahl U, Nößner E, Kronenberger K et al. Vaccination against B-cell chronic lymphocytic cells with trioma cells: preclinical evaluation. Clin Cancer Res 2003; 9: 4240–4246.

    CAS  PubMed  Google Scholar 

  40. Meidenbauer N, Marienhagen J, Laumer M et al. Survival and tumor localization of adoptively transferred melan-A-specific T cells in melanoma patients. J Immunol 2003; 170: 2161–2169.

    Article  CAS  Google Scholar 

  41. Oelke M, Maus MV, Didiano D et al. Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells. Nat Med 2003; 9: 619–624.

    Article  CAS  Google Scholar 

  42. Blankenstein T, Qin Z . The role of IFN-γ in tumor transplantation immunity and inhibition of chemical carcinogenesis. Curr Opin Immunol 2003; 15: 148–154.

    Article  CAS  Google Scholar 

  43. Qin Z, Schwartzkopff J, Pradera F et al. A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells. Cancer Res 2003; 63: 4095–4100.

    CAS  PubMed  Google Scholar 

  44. Schuler T, Kornig S, Blankenstein T . Tumor rejection by modulation of tumor stromal fibroblasts. J Exp Med 2003; 198: 1487–1493.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, Louisiana State University Health Sciences Center, Shreveport, LA, USA

    R Munker

  2. Medizinische Klinik III der Ludwig-Maximilians-Universität (Klinikum Grosshadern), Munich, Germany

    C Schmid & H J Kolb

  3. The Antony Nolan Research Institute, London, UK

    J A Madrigal

  4. GSF Clinical Cooperative Group for Hematopoietic Cell Transplantation, Munich, Germany

    H J Kolb

Authors
  1. R Munker
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C Schmid
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J A Madrigal
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H J Kolb
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R Munker.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Munker, R., Schmid, C., Madrigal, J. et al. An update on graft-versus-host and graft-versus-leukemia reactions: a summary of the sixth International Symposium held in Schloss Ellmau, Germany, January 22–24, 2004. Bone Marrow Transplant 34, 767–780 (2004). https://doi.org/10.1038/sj.bmt.1704667

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704667

Keywords

This article is cited by

Search

Advanced search

Quick links